Aberdeen Group’s Fulcrum Therapeutics FULC Stock Holding History

Aberdeen Group’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,211,953	Closed	-$17M	–	952
2026 Q1	$17M	Buy	2,211,953 +957,926	+76%	+$8.89M	0.03%	468
2025 Q4	$14.2M	Buy	1,254,027 +1,116,066	+809%	+$11.4M	0.02%	534
2025 Q3	$1.27M	Buy	137,961 +79,265	+135%	+$573K	﹤0.01%	819
2025 Q2	$404K	Buy	+58,696	New	+$314K	﹤0.01%	901
2024 Q3	–	Sell	-256,888	Closed	-$1.59M	–	936
2024 Q2	$1.59M	Hold	256,888	–	–	﹤0.01%	777
2024 Q1	$2.43M	Hold	256,888	–	–	﹤0.01%	755
2023 Q4	$1.73M	Buy	+256,888	New	+$1.14M	﹤0.01%	785

Other funds holding FULC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Aberdeen Group's FULC Position: Q2 2026 in Review

Aberdeen Group sold out of Fulcrum Therapeutics (FULC) in Q2 2026, closing a stake of 2,211,953 shares — an estimated $17M sold.

Aberdeen Group first reported a position in FULC in Q4 2023 and held it in 7 quarters. The position peaked at $17M in Q1 2026. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

Aberdeen Group reported no remaining Fulcrum Therapeutics position as of Q2 2026 after selling out during the quarter.
Aberdeen Group sold 2,211,953 Fulcrum Therapeutics shares in Q2 2026, an estimated $17M.
Aberdeen Group first reported a position in Fulcrum Therapeutics in Q4 2023 and held it in 7 quarters.
Aberdeen Group's Fulcrum Therapeutics position peaked at $17M in Q1 2026.
155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.